SCHEDULE 13G/A 0000947871-25-000782 0001055951 XXXXXXXX LIVE 1 Common Stock, par value $0.00001 per share 12/31/2025 0001501989 CytomX Therapeutics, Inc. 23284F105 151 Oyster Point Blvd. Suite 400 South San Francisco CA 94080 Rule 13d-1(c) OrbiMed Advisors LLC DE 0.00 3525650.00 0.00 3525650.00 3525650.00 N 2.1 IA CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, California, 94080 OrbiMed Advisors LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Delaware N IA 3,525,650 2.1% 0 3,525,650 0 3,525,650 N Y N The Reporting Person holds 2.1% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. OrbiMed Advisors LLC /s/ Carl L. Gordon 02/17/2026